Needham & Company
View Older Stories
-
Needham Reiterates Buy Rating on Hologic (HOLX)
-
Needham Reiterates Buy Rating on Hologic (HOLX)
-
Needham Reiterates Buy Rating on Hologic (HOLX)
-
Hologic to Webcast Presentations at Upcoming Investor Conferences
-
Hologic (HOLX) shares undervalued - Needham & Company
-
Needham & Company Upgrades Hologic (HOLX) to Buy as COVID-related headwind will soon end
-
Companies with NDRs 09/26
-
Hologic (HOLX) PT Raised to $52 at Needham & Company
-
Hologic (HOLX) PT Raised to $50 at Needham & Company
-
Pre-Open Movers 08/13: (NLSN) (DBD) (TSLA) Higher; (DY) (SSC) (HOLX) Lower (more...)
-
Hologic (HOLX) PT Raised to $48 at Needham & Company
-
FDA MQSA Statistics A Modest Positive For Hologic (HOLX) - Needham
-
Hologic (HOLX) PT Lowered to $43 at Needham & Company; 'Ugly Write-Down for Aesthetics Business'
-
Hologic (HOLX) PT Raised to $48 at Needham & Company Following MQSA Update
-
Hologic (HOLX): Aesthetics Miss Overshadows Improvement in Other Areas - Needham
-
Needham & Company Upgrades Hologic (HOLX) to Buy Following Cynosure Deal
-
Needham & Company Reiterates Hold on Hologic (HOLX) Following Announced Sale of Blood Screening Business
-
ResMed (RMD), St. Jude (STJ), Cepheid (CPHD) Among Med Tech Companies with Most EU Exposure - Needham & Company
-
Needham & Company Downgrades Hologic (HOLX) to Hold
-
Needham & Company Upgrades Hologic (HOLX) to Buy
-
Needham & Company Downgrades Hologic (HOLX) to Hold
-
Hologic (HOLX) PT Raised to $33 at Needham & Company on Strong Q1 Growth Acceleration
-
Hologic (HOLX) PT Raised to $30 at Needham & Company on JAMA Study
-
Hologic (HOLX) Buy Reiterated a Needham & Company Post Q2 on 'Encouraging' Return to Rev Growth
-
Hologic (HOLX) Q1 a Small Step Toward Rebuilding Credibility, Needham & Company Says
-
After Serious Outperformace in 2013, Needham & Company Lays Out 2014's Top Stock Picks
-
Hologic (HOLX) New CEO First Major Step in Turnaround - Needham & Company
-
Hologic (HOLX) Sum-of-Parts Worth $29/Sh - Needham & Company
-
Icahn Could Accelerate Hologic (HOLX) Strategic Moves - Needham & Company
-
Notable Analyst Rating Changes 10/02: (VLO) (BCS) (ABX) Upgraded; (PGR) (TSLA) (AA) Downgraded
-
Needham & Company Starts Hologic (HOLX) at Buy
-
Streetinsider.com Pre-Open Movers 07/19: (OXGN) (ASTX) (SWKS) Higher; (ISRG) (MSFT) (CYH) Lower (more...)
-
Notable Analyst Rating Changes 08/03: (WFM) (CI) (HOLX) Upgraded; (NOK) (MTG) (ZIP) Downgraded
-
Needham & Company Reiterates a 'Buy' on Hologic (HOLX); Waiting 'Til November for GPRO Insight
-
Needham & Company Maintains a 'Buy' on Hologic (HOLX); Qtr In-line; Acquisition on Gen-Probe is Transformational
-
Needham & Company Reinstates Coverage on Hologic (HOLX) at Buy; The 3-D Upgrade Cycle is Just Around the Corner
-
Needham & Company Reiterates a 'Buy' Rating on Hologic (HOLX); FDA Panel Votes In Favor Of 3D Mammography
-
Needham & Company Reiterates a 'Buy' Rating on Hologic (HOLX); FDA Panel on Sept 24 Potential Catalyst
-
Notable Analyst Rating Changes 06/03: HOLX, SCHW, KEY, EBAY Upgraded; DIVX, BP, CWTR, ACAS Downgraded
-
Needham & Company Upgrades Hologic (HOLX) to Buy; Survey Data Supports Emerging Upgrade Cycle for Digital Mammography
-
Needham & Company Reiterates a 'Hold' on Hologic (HOLX); F2Q10 Topline Beat, Guidance Below Expectations
-
Notable Analyst Rating Changes 8/4: HBC, HGSI, PKY, DISH, TLB Upgraded; HOLX, ATML, ABX, STEC, LAMR Downgraded
-
Notable Analyst Rating Changes 4/14: BRCD, ALB, DPS, OMI, PL Upgraded; SNDA, BYD, STX, ESI Downgraded
-
Needham Downgrades Hologic (HOLX) to Hold
-
Notable Analyst Rating Changes 2/14: BIDU, VCLK, CHK Upgraded; LVLT, NHWK, IM Downgraded

